Erratum

This article refers to:

Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections

McBride D, Krekel T, Hsueh K, et al. Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections. Expert Opin Drug Metab Toxicol. 2017;13(3):331–337.

Available from http://dx.doi.org/10.1080/17425255.2017.1290080

When the above article was published, the contents of Tables 1 and 2 were swapped in error. The correct versions of Tables 1 and 2 are given below.

Table 1. Pharmacokinetic parameters of linezolid and tedizolid [42,44,45,52].

	Tedizolid phosphate (200 mg PO once daily)	Linezolid (600 mg PO twice daily)
Cmax (mg/L)	2.2 ± 0.6	21.2 ± 5.78
Tmax (hours)	3.5 (1.0 to 6.0 – median range)	1.03 ± 0.62
T½ (hours)	12	5.4 ± 2.06
Clearance (L/hr)	8.4 ± 2.1	4.8 ± 1.74
AUC (mcg*hr/mL)	25.6 ± 8.4	138 ± 42.1

Table 2. Common side effects of tedizolid and linezolid based on phase 3 clinical trials [11,48].

Side-effect reported	Percent of pts with adverse-effects (%)
	Tedizolid group (%)	Linezolid group (%)
Headache	6.2	5.9
Nausea	8.2	12.2
Vomiting	2.9	5.6
Dyspepsia	0.6	1.2
Constipation	1.4	0.9
Diarrhea	3.9	5.3
Dizziness	1.8	2.1
Pruritus	0.5	1.4
Fatigue	1.4	1.8
Insomnia	1.5	0.8

Taylor & Francis apologizes for this error.